CTC Clinical Trial Consultants AB

The site leverages advanced PET imaging and biomarker platforms to enhance early detection and monitoring across a spectrum of conditions, ranging from neuro‑degenerative disorders to metabolic liver disease.

• Development of novel PET tracers for liver fibrosis assessment
• Imaging of alpha‑7 nicotinic acetylcholine receptors in Alzheimer’s disease research
• Validation of diagnostic biomarkers for invasive bacterial infections

These efforts aim to improve diagnostic accuracy, support therapeutic decisions, and ensure safety of emerging imaging agents.

Research focuses on preventing serious bacterial diseases such as invasive Escherichia coli infections and pneumococcal illness through innovative vaccine strategies.

• Evaluation of a multivalent ExPEC9V vaccine in older adults
• Safety and immunogenicity study of the V116 pneumococcal conjugate vaccine in children and adolescents
• Assessment of serotype‑specific opsonophagocytic activity post‑vaccination

The goal is to reduce the burden of bacterial infections in high‑risk populations by establishing effective preventive immunizations.

Clinical programs target major heart‑related conditions, including heart failure with reduced ejection fraction and primary prevention of atherosclerotic events, using innovative therapeutic agents.

• Investigation of inclisiran for lowering major adverse cardiovascular events
• Study of AZD3427’s impact on renal cortex perfusion in HFrEF patients with renal impairment
• Exploration of novel lipid‑lowering strategies to support ASCVD prevention

These trials seek to improve survival, reduce hospitalizations, and enhance quality of life for patients with cardiovascular risk.

The research agenda addresses disorders of the gastrointestinal tract and liver, from celiac disease to advanced fibrosis, emphasizing both symptom relief and disease modification.

• Clinical evaluation of ZED1227 for persistent celiac disease symptoms
• PET tracer study for non‑invasive assessment of liver fibrosis and steatotic liver disease
• Investigation of therapeutic approaches for primary sclerosing cholangitis and Crohn’s disease complications

The overarching aim is to provide patients with better management options and to refine diagnostic tools for gastrointestinal health.

A dedicated program evaluates new pharmacologic options for Erectile dysfunction, seeking to expand treatment choices beyond existing therapies.

• Safety and efficacy assessment of LIB‑01 in men with erectile dysfunction
• Comparative analysis of LIB‑01 against standard of care outcomes
• Monitoring of adverse events to ensure tolerability

The purpose is to introduce a novel, well‑tolerated solution that improves sexual health and patient confidence.

Research spans neurodegenerative and headache disorders, integrating both pharmacologic and imaging studies to alleviate symptoms and explore disease mechanisms.

• Alpha‑7 nicotinic receptor PET study in Alzheimer’s disease and mild cognitive impairment
• Rimegepant trials for migraine prevention and acute treatment in patients with inadequate response to existing preventives
• COMP360 evaluation for treatment‑resistant depression with psychological support
• Eptinezumab add‑on therapy for migraine accompanied by medication overuse headache

These initiatives aim to reduce neurological burden, improve daily functioning, and validate new therapeutic pathways.

The site investigates metabolic health challenges such as obesity, steatotic liver disease, and renal impairment, focusing on both therapeutic and diagnostic innovations.

• AZD3427’s effect on renal perfusion in heart‑failure patients with reduced kidney function
• Imaging studies to track metabolic dysfunction‑associated steatotic liver disease progression
• Exploratory trials targeting obesity‑related pathways to improve metabolic outcomes

Objectives include clarifying disease mechanisms, enhancing patient monitoring, and identifying effective interventions for metabolic disorders.

Ongoing work addresses acute viral threats, notably COVID‑19, by testing antiviral agents that could lessen disease severity in high‑risk groups.

• Evaluation of Bemnifosbuvir’s ability to reduce hospitalization and death in outpatient COVID‑19 cases
• Safety monitoring of antiviral therapy in diverse patient populations
• Assessment of supportive care outcomes alongside antiviral treatment

The trials strive to expand therapeutic options that can mitigate the impact of viral infections and improve recovery rates.

Focused investigations target severe psychiatric conditions, with an emphasis on patients who have not responded to conventional therapies.

• COMP360 administration protocol for adults with treatment‑resistant depression
• Evaluation of symptom improvement and functional recovery over six weeks
• Integration of psychological support to enhance treatment efficacy

The aim is to provide new hope for individuals with persistent depressive symptoms and to broaden the therapeutic arsenal for mental health professionals.